This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Original article
Wechsler, M. E. et al. Benralizumab versus mepolizumab for eosinophilic granulomatosis with polyangiitis. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2311155 (2024)
Related article
Emmi, G. et al. Evidence-Based Guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis. Nat. Rev. Rheumatol. 19, 378–393 (2023)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Onuora, S. Benralizumab noninferior to mepolizumab for EGPA. Nat Rev Rheumatol 20, 253 (2024). https://doi.org/10.1038/s41584-024-01116-6
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41584-024-01116-6